DR Congo Rolls Out Ebola Vaccine for Frontline Health Workers as Death Toll Rises

Health workers in the Democratic Republic of the Congo have begun receiving an Ebola vaccine as part of a major public health rollout aimed at protecting medical staff in the country's northeast. The vaccination campaign started on Saturday in Bunia, the capital of Ituri province, which serves as the epicentre of what health officials describe as the fastest-growing Ebola outbreak in history.

According to Al Jazeera, the provincial governor, Major-General Gaby Kasongo Mulumba, emphasized that healthcare workers in the region "are particularly exposed and deeply involved in the response." The immunization effort is backed by the World Health Organization and Doctors Without Borders, known internationally by its French initials MSF. Following the initial rollout in Bunia, health authorities plan to expand the campaign into North Kivu province, where infection numbers have also climbed sharply.

The vaccination initiative targets approximately 50,000 healthcare and other frontline workers who will receive the Ervebo vaccine. While Ervebo was originally developed to target the more common Zaire strain of the virus, health officials are closely monitoring its performance against the current outbreak, which is caused by the Bundibugyo virus. As part of this monitoring, 20,000 vaccine recipients will be enrolled in a one-year clinical trial to track its efficacy.

Current clinical trials continue as researchers search for a fully licensed vaccine tailored specifically to the latest outbreak. At present, the ongoing epidemic lacks a dedicated licensed vaccine or proven medical treatment. Steve Ahuka, a Congolese official serving on the national Ebola health task force, noted the uncertainty surrounding the cross-strain protection, stating that experts do not yet know to what degree the vaccine might be effective against the Bundibugyo strain.

Despite the uncertainties, many frontline workers have embraced the measure as a necessary precaution. Dr Jeannot Elua, speaking at a health facility in Bunia, told the Associated Press that healthcare workers do not really have a choice and must receive it for protection. He added that some individuals in the area had previously received the earlier iteration of the vaccine on a mandatory basis.

World Health Organization experts have pointed to early data, notably from animal trials, indicating that the Ervebo vaccine could potentially offer some level of cross-protection during the current epidemic. In August, the WHO approved 70,000 doses of Ervebo for deployment in the DRC. The vaccine is currently being administered under a compassionate-use programme, a regulatory pathway that permits the deployment of unapproved medical products during severe public health crises when specific treatments are unavailable.

The rollout comes against the backdrop of a severe and mounting human toll. According to figures from local authorities cited by Al Jazeera, the outbreak has resulted in at least 3,639 deaths and approximately 7,541 total infections since it began in May. At the same time, at least 1,823 people have successfully recovered from the virus.

Public health agencies remain divided on the immediate trajectory of the epidemic. While WHO officials highlighted encouraging signs that overall transmission rates may be slowing down, Doctors Without Borders issued a stark warning that clear evidence is lacking to definitively state that the epidemic is coming under control. The ongoing response underscores the persistent challenges faced by medical personnel operating in eastern DR Congo as they battle a complex and lethal viral strain.